Cryoport Q2 revenue up 14% to $64.2M; net loss widens to $0.23/sh; guidance reaffirmed

Cryoport, Inc.

2022-Q2 EPS reported -$0.54 revenue$116,455,000

Revenue $64.2M (+14% YoY, +18% constant currency); Biopharma/Pharma $51.7M (+14%).
Net loss to common $11.2M ($0.23/sh) vs $7.4M ($0.16) in Q2 2021; GAAP net loss $9.2M.
Adjusted EBITDA $6.0M, flat YoY; gross margin 45.0%, steady YoY and up 224bps sequentially.
FY2022 revenue guidance reaffirmed at $260M-$265M; $33.3M share repurchase completed at avg $24.84.
Record 626 clinical trials supported; opened new Global Supply Chain Centers; closed three acquisitions in Europe.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.